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 Obtaining consent for neonatal research 
Informed consent is given when a competent person who has received and understood 
sufficient information voluntarily decides whether or not to receive treatment or take 
part in research.  It is widely seen as an essential component of most medical 
research.  In the case of neonates, parents must make the decision.  However, there 
are a number of reasons to think that such consent is not likely to meet the criteria for 
being genuine informed consent.   
 
1. Neonatal research often takes place in fraught circumstances.  Parents may be 
suffering the emotional shock of unexpectedly having given birth to a 
seriously ill baby. 
2. The need for consent may be urgent; in other words, there may only be a few 
hours in which the parents are able to decide (as in birth asphyxia trials). 
3.  The trial may be an “emergency trial” (1).  These trials combine an urgent 
need for consent with the fact that the research is into interventions that are 
aimed at dealing with a life threatening condition (e.g. ECMO [2]).   
4. The trial may involve a number of complexities.  These may be difficult for 
lay-people to understand, particularly when under stress.   
 
In other words, the anguished parent of a severely ill baby has to process very 
complex information and make a decision on behalf of that child in a short period of 
time.   It is hardly surprising that clinicians have long doubted that such decisions 
constitute informed consent.  These doubts seem to be confirmed by recent research 
(3,4).   
 
One of these research projects, the Euricon trial (4), involved neonatologists, ethicists 
sociologists and legal experts from 11 European countries.  Their discussions of 
possible improvements to the informed consent process form the basis of this 
editorial.   
 
Not all neonatal trials are “fraught”.  There are, for example, feeding trials, where 
there is plenty of time to obtain consent, and where the background condition of the 
neonate may not be worrying.  One of the surprises of the Euricon research was that 
the standard of consent often seemed poor even in these types of projects.  This 
suggests that those obtaining consent could do better.  Researchers often seemed 
unaware of legal or Research Ethics Committee (REC) guidelines governing the 
process in their geographical area.  This situation seems likely to improve as medical 
students are increasingly expected to address such issues in their training (5).  
However, formal training should be available to those who do not.   
 
A second area for improvement relates to the information sheet.  Many parents do not 
read this sheet or fail to do so prior to consent (1).  Thus, one way to improve the use 
of information sheets is to draw them up with a trial specific checklist of points of 
information that the researcher can then go through with parents prior to their consent 
decision. 
 
These sorts of measures may improve the general quality of parental consent.  
However, this leaves the problem of the apparent impossibility of achieving a 
reasonable standard of informed consent in situations of urgency and emergency.  
How can we tackle this problem?  There are a number of possibilities.   
 1. Two alternative consent procedures 
We should accept that there is likely to be a significant reduction in the quality of 
parental consent in the “fraught” trials.  Clinicians may give all the relevant 
information, but the parents may not have the capacity to understand and process that 
information in the time available.  There are two possible alternative consent 
procedures here.   
 
The first is a step-like process of consent.  This involves giving parents a bare 
minimum of information (that which is most important for parents to understand) 
prior to enrolling the infant in a trial; then giving more information and repeating the 
request for consent as time goes on.  Information sheets should be adjusted 
accordingly.  Parents would receive a preliminary information sheet with a short 
series of points for the clinician to go through with them.   
 
It might be argued that once parents have committed themselves on the basis of 
limited information they will find it hard to withdraw when they gain fuller 
information.  This would raise concerns about the voluntariness of parents’ decisions 
to remain in a trial following their original consent.   
 
However, these concerns arise equally with a standard consent procedure; for whilst 
parents may have received all the relevant information, they may not have understood 
and processed it.  They are likely to do this only later (when the research is under 
way).  The virtue of the step-like approach is that it enables the researcher to focus 
parents’ attention on a bare minimum of crucial information, and to emphasise 
voluntariness then and later.  The “bare minimum” would include that: the treatment 
is being given as part of a trial; their child may be receiving experimental or unproven 
treatment; they are free to say “no” and opt for the standard treatment; this is 
preliminary information and that more information is available if they wish to see it 
now (and will be given to them anyway, at a future point). 
 
However, a further concern with the step-like approach is that parents may find that 
they receive information later in the research process that would have caused them to 
refuse consent had they received it earlier.  This leads us to the second alternative 
consent procedure; the continuous consent approach.  This involves giving parents all 
information at the outset (and asking for their consent) and then repeating this at later 
stages in the research.  This avoids the problems of step-like consent whilst sharing 
the virtue of recognising that parents may not truly have understood first time round.  
However, it lacks the virtue of enabling the researcher to focus on a core of essential 
information.  Neither of these approaches has been formally assessed. 
 
2. Recognising the limited role of parental consent 
If the role of parental informed consent were to protect the neonatal research subject, 
then our acceptance that the consent process is sometimes less than ideal would seem 
to imply that research subjects have reduced protection in such cases.  This would not 
be acceptable.  Hence, parental informed consent should not be seen as being the sole 
or main safeguard of the neonate's welfare in research.  Researchers drawing up 
proposals, grant-giving and professional bodies, senior staff within the hospital 
structure undertaking a scientific review process and RECs considering the proposals 
have independent responsibility for the welfare of the child and to ensure that parents 
are not asked to consent to bad research (6).   The role of parental consent should be 
to do with respecting parents as decision makers for their children.  Protecting 
neonates’ welfare should be the concern of all involved. 
 
3. Informing parents about RECs 
If we accept this last point, then parents are unnecessarily burdened if they feel that 
their consent decision is of great import to their child’s welfare.  This could be eased.  
The Euricon study found that parents were usually unaware of the fact that the 
proposed research had been scrutinised by an REC.  Some said it would have helped 
them if they had known this.  As such, information sheets should include the fact an 
independent committee (an REC) has approved the research (7).   Parents should be 
aware that such approval is consistent with its being both reasonable to give or to 
withhold their consent. Such a statement would need careful wording to prevent its 
coercing or cajoling parents to enter children into trials.  The following is a proposed 
formulation. 
 
“You have been asked to consider whether or not you wish to enter your baby into the 
x trial.  An independent research ethics committee (REC) has looked at the overall 
likely health risks and benefits of the trial and have given it their approval.  You are 
still entirely free to decide whether or not you want to enter your child into this 
research.  Whatever you decide, your child will receive the best possible care.” 
 
4. Doing without informed consent? 
There may be situations in which even step-like consent fails.  For example, the time 
available in which to obtain consent may be so short that it is not possible for most 
parents to digest even the basic minimum of information.  At this point, the key 
decision must be whether or not to do the research.  Euricon partners were divided on 
this: some felt strongly that neonatal research without parental consent should never 
occur, others that in extremis it should.    
 
The Helsinki declaration does allow for research to take place, “on individuals from 
whom it is not possible to obtain consent, including proxy or advance consent … [but] 
only if the physical/mental condition that prevents obtaining informed consent is a 
necessary characteristic of the research population” (8 [at B26]).   
   
Arguably, neonates with parents in the extreme situations hypothesized would meet 
this criterion.  As such, perhaps there will be rare occasions on which neonatal 
research ought to be allowed at least to begin without parental consent.  If so there 
would have to be further safeguards.  One would be especially careful review by the 
relevant RECs; another that parents are informed on admission to hospital that 
research occurs in the hospital, and allowed to put in place a blanket refusal on all 
research.   
 
Finally, the measures discussed in this paper might be described as “supply side”; 
implemented by clinicians on behalf of parents.  Organisations such as Consumers for 
Ethics in Research (CERES) (9) and the Cochrane Collaboration Consumer Network 
(10) show that we should not neglect “demand side” measures.  Thus, for example, 
any proposal for non-consensual research might first be put out to community 
consultation (an American model implemented following a Food and Drug 
Administration amendment to consent regulations [11]).  Similarly, such consultation 
could occur if the “step-like” consent model, outlined above, were proposed.  
However, the benefits of such consultation need to be set against concerns such as 
delaying the research and the difficulty of finding citizens genuinely representative of 
research participants. 
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